Does retatrutide cause skin burning or tingling?

Yes, it has been reported. Phase 3 TRIUMPH trials reported dysaesthesia (skin burning or tingling) in about 6–21% at higher doses versus about 1% on placebo, and users here describe burning or pins-and-needles skin.

Does retatrutide raise heart rate?

Trials found a dose-dependent increase in heart rate. Palpitations or a racing heart need medical review.

What are common retatrutide side effects?

In our anonymous file, gastrointestinal phrases (nausea, constipation and related) dominate, similar to other incretin stories. See the live report for counts — they are not clinical incidence.

Is retatrutide approved?

It remains investigational for routine care in major markets; it is not a substitute for approved labelled medicines.

How many user reports?

The live retatrutide side-effects report uses 334 published anonymous confessions.

Retatrutide Side Effects: What Labels and Users Report

Retatrutide side effects from 334 anonymous user reports plus investigational-drug context. Phrase matches, not clinical rates. Not medical advice.

Anonymous user report. Not medical advice. Peptides discussed are not FDA-approved for the uses described. Editorial process →

Short answer

Retatrutide is an investigational triple agonist (GLP-1, GIP and glucagon pathways) — not an approved finished drug for routine prescribing in the way Ozempic or Mounjaro are. Community side-effect stories still cluster on gastrointestinal effects (nausea, constipation, vomiting) and other themes scored in our live report. Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

What the trials found

Retatrutide is a triple agonist (GLP-1, GIP and glucagon receptors) from Eli Lilly, not approved by any regulator as of October 15, 2026; Lilly has said it plans to file with the FDA in the first quarter of 2027. In the phase 2 trial (NEJM 2023), GI effects were the most common and dose-related, and heart rate rose in a dose-dependent way, peaking around six months. Across the four core phase 3 TRIUMPH trials, Lilly reports dysaesthesia (a skin burning or tingling sensation, mostly mild to moderate) in about 6–21% at the higher doses versus about 1% on placebo, highest (21%) in TRIUMPH-4. That is not a typical effect of semaglutide or tirzepatide. In TRIUMPH-4, 12–18% stopped because of side effects versus 4% on placebo.

Effect	Retatrutide trials	Versus approved GLP-1s
Nausea, vomiting, diarrhoea, constipation	Most common; dose-related	Similar class
Heart rate increase	Dose-dependent rise	Smaller rises
Skin sensitivity (dysaesthesia)	About 6–21% at higher doses vs 1% placebo	Not a typical effect
Long-term safety	Limited to trial follow-up	Years of data

What users describe

Because retatrutide is unapproved, every confession here involves unregulated product. Skin symptoms stand out: #289 describes skin that "felt like it was on fire", pins and needles that faded after cutting back; #546 lists exhaustion, feeling cold and "skin hurts all the time". #349 predicts the racing heart, skin sensitivity and insomnia will put many people off.

GI effects are constant: #39 says "stomach destroyed + daily nausea + vomiting"; #826 describes constipation and sugar cravings at 16 weeks. Mood comes up often: #810 says it "killed my hunger & personality", #831 describes anxiety taking over. #817 discovered a pregnancy while using it, a reminder that unapproved drugs have no pregnancy safety data.

Last reviewed

October 15, 2026.

Live counts on this site

As of the live report there are 334 published anonymous confessions tagged retatrutide. Phrase-match tables, timelines and methodology: retatrutide side-effects report. Hub: retatrutide.

Compared with approved GLP-1s

Retatrutide vs tirzepatide, retatrutide vs semaglutide, Mounjaro side effects. Retatrutide is not authorized the same way; quality of grey-market products is a separate risk.

More confessions from the archive

Community Q&A

Does retatrutide cause skin burning or tingling?: Yes, it has been reported. Phase 3 TRIUMPH trials reported dysaesthesia (skin burning or tingling) in about 6–21% at higher doses versus about 1% on placebo, and users here describe burning or pins-and-needles skin.
Does retatrutide raise heart rate?: Trials found a dose-dependent increase in heart rate. Palpitations or a racing heart need medical review.
What are common retatrutide side effects?: In our anonymous file, gastrointestinal phrases (nausea, constipation and related) dominate, similar to other incretin stories. See the live report for counts — they are not clinical incidence.
Is retatrutide approved?: It remains investigational for routine care in major markets; it is not a substitute for approved labelled medicines.
How many user reports?: The live retatrutide side-effects report uses 334 published anonymous confessions.
Does this page give dosing advice?: Peptide Confessions does not publish dosing, timing, injection or sourcing guidance.

Sources

Anonymous first-hand reports plus sourced context — educational only, not medical advice. Editorial policy & corrections.